Cargando…

The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial

BACKGROUND: The prognostic value and optimal resection outcome related factors of the secondary cytoreduction surgery (SCR) in Platinum-sensitive recurrent ovarian cancer (PSOC) patients were still in doubt. The present retrospective study aims to determine the relationship between the objective res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Hongyuan, Zhou, Rui, Ni, Jing, Xu, Xia, Cheng, Xianzhong, Li, Yan, Chen, Xiaoxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298741/ https://www.ncbi.nlm.nih.gov/pubmed/32546257 http://dx.doi.org/10.1186/s13048-020-00673-0

Ejemplares similares

Why was GOG-0213 a negative trial?
por: Ehmann, Sarah, et al.
Publicado: (2020)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Gog
por: Papini, Giovanni, 1881-1956
Publicado: (1980)

Gog
por: Papini, Giovanni, 1881-1956
Publicado: (1932)

Gog
por: Papini, Giovanni, 1881-1956
Publicado: (1961)

Gog
por: Papini, Giovanni, 1881-1956
Publicado: (1964)

Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer
por: Ni, Jing, et al.
Publicado: (2020)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Gog und mogog : eine chronik
por: Buber, Martin, 1878-1965
Publicado: (1957)

Gog ; El libro negro
por: Papini, Giovanni, 1881-1956
Publicado: (1984)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer
por: Raj, Hemanth, et al.
Publicado: (2021)

OA02.13. Effects of drakshavaleha in developing mice embryo
por: Kumar, Sunil
Publicado: (2013)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Evaluation of anti-inflammatory and antimicrobial activity of AHPL/AYTOP/0213 cream
por: Nipanikar, Sanjay U., et al.
Publicado: (2017)

High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis
por: Guo, Wenwen, et al.
Publicado: (2021)

Divertimientos lingüisticos de gog y magog /
por: Tibón, Gutierre, 1905-
Publicado: (1947)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study
por: Amira, Gamal, et al.
Publicado: (2019)

EHMTI-0213. Does prior craniofacial nociception lead to an increase in cortical excitability?
por: Supronsinchai, W, et al.
Publicado: (2014)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
por: Verdegaal, Els M E, et al.
Publicado: (2023)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
por: Pelissier, Aurélie, et al.
Publicado: (2016)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
por: Ni, Jing, et al.
Publicado: (2021)

Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma
por: Zhang, Kai, et al.
Publicado: (2020)

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
por: Ni, Jing, et al.
Publicado: (2021)

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China
por: Ni, Jing, et al.
Publicado: (2022)

Complete Genome Sequence of a Novel Clinical Isolate, Mycobacterium abscessus Strain NOV0213
por: Dymova, M. A., et al.
Publicado: (2016)

Successful secondary radical operation on unretractable metastatic platinum-sensitive recurrent ovarian cancer by immunotherapy: a case report
por: Sun, Li, et al.
Publicado: (2022)

ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy
por: Yasukawa, Maya, et al.
Publicado: (2016)

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
por: Monk, Bradley J, et al.
Publicado: (2021)

The Evaluation Value of CT in the Efficacy of Neoadjuvant Chemotherapy in Ovarian Cancer Patients
por: Mou, Daying, et al.
Publicado: (2022)

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
por: López-Guerrero, José Antonio, et al.
Publicado: (2015)

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
por: Ni, Jing, et al.
Publicado: (2020)

WCN23-0213 PROXIMAL TUBULAR DYSFUNCTION AS A PREDICTOR OF AKI IN HOSPITALIZED COVID-19 PATIENTS
por: ALIMUL BARI, A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4m4sa1at34e8es8a6lhr7bjn2g